Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I, Dose Escalation Study of BNC101 (Anti-LGR5 Humanized Monoclonal Antibody) in Patients With Metastatic Colorectal Cancer.

NCT02726334 is registered in ClinicalTrials.gov with Bionomics Limited as lead sponsor.

NCT NCT02726334
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02726334 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I, Dose Escalation Study of BNC101 (Anti-LGR5 Humanized Monoclonal Antibody) in Patients With Metastatic Colorectal Cancer.
Lead sponsor
Bionomics Limited
Phase
Phase 1
Overall status
Terminated
Start date
March 31, 2016
Completion date
February 28, 2018
Enrollment
22 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

colorectal cancer